company background image
1IY0 logo

Monopar Therapeutics DB:1IY0 Stock Report

Last Price

€31.20

Market Cap

€278.2m

7D

0%

1Y

2,112.8%

Updated

07 Feb, 2025

Data

Company Financials +

Monopar Therapeutics Inc.

DB:1IY0 Stock Report

Market Cap: €278.2m

1IY0 Stock Overview

A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. More details

1IY0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 73.4% below our estimate of its fair value

Risk Analysis

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Monopar Therapeutics Inc. Competitors

Heidelberg Pharma

XTRA:HPHA

€110.9m

Formycon

XTRA:FYB

€932.3m

2invest

XTRA:2INV

€67.8m

4SC

DB:VSC

€61.3m

Price History & Performance

Summary of share price highs, lows and changes for Monopar Therapeutics
Historical stock prices
Current Share PriceUS$31.20
52 Week HighUS$31.80
52 Week LowUS$1.38
Beta1.31
1 Month Changen/a
3 Month Changen/a
1 Year Change2,112.77%
3 Year Change147.62%
5 Year Changen/a
Change since IPO-32.93%

Recent News & Updates

Recent updates

Shareholder Returns

1IY0DE BiotechsDE Market
7D0%1.1%-0.02%
1Y2,112.8%-3.7%15.1%

Return vs Industry: 1IY0 exceeded the German Biotechs industry which returned -2.6% over the past year.

Return vs Market: 1IY0 exceeded the German Market which returned 15.3% over the past year.

Price Volatility

Is 1IY0's price volatile compared to industry and market?
1IY0 volatility
1IY0 Average Weekly Movementn/a
Biotechs Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 1IY0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 1IY0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201410Chandler Robinsonwww.monopartx.com

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.

Monopar Therapeutics Inc. Fundamentals Summary

How do Monopar Therapeutics's earnings and revenue compare to its market cap?
1IY0 fundamental statistics
Market cap€278.16m
Earnings (TTM)-€6.27m
Revenue (TTM)n/a

0.0x

P/S Ratio

-45.6x

P/E Ratio

Is 1IY0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1IY0 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$6.47m
Earnings-US$6.47m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.06
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 1IY0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 15:06
End of Day Share Price 2025/01/28 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Monopar Therapeutics Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Brian Kemp DolliverBrookline Capital Markets
Sean LeeH.C. Wainwright & Co.